Investors of Capricor Therapeutics Have Opportunity to Lead Major Securities Fraud Lawsuit

Overview of the Capricor Therapeutics Securities Fraud Lawsuit

On August 3, 2026, the Rosen Law Firm announced a class action lawsuit on behalf of investors who purchased securities in Capricor Therapeutics, Inc. (NASDAQ: CAPR) during the defined class period from December 17, 2025, to July 26, 2026. This legal action comes after serious allegations were raised concerning misleading statements made by the company regarding its clinical trials and regulatory approvals.

Background on Capricor Therapeutics

Capricor Therapeutics is a biotechnology company focused on the development of innovative therapies for serious medical conditions, especially those related to Duchenne muscular dystrophy. Their lead product, Deramiocel, has been pivotal in their clinical studies and promises significant advancements in treatment methods.

The Class Action Lawsuit

The class action lawsuit is designed to provide a platform for investors who may have suffered losses due to potentially false statements made by Capricor's executives. It intends to hold the company accountable for not disclosing necessary information regarding their clinical data analysis and FDA approval processes. Investors who joined the lawsuit will have the opportunity to recover damages incurred during the class period.

Defendants' Allegations

The Rosen Law Firm's lawsuit claims that the Capricor executives made materially false or misleading statements, including:
1. Unapproved changes were made to the analysis plan used for clinical data relating to Deramiocel.
2. The FDA's consent was not obtained for these changes prior to resubmitting the Biologics License Application (BLA) for Deramiocel.
3. This created a significant risk that the FDA could reject the application due to insufficient evidence of effectiveness.
4. Consequently, the company misled investors about the potential for regulatory approval and the overall future of its business.

When the information became public, the market reacted negatively, resulting in substantial losses for affected investors.

How to Participate in the Lawsuit

For those who purchased Capricor securities during the class period, joining the lawsuit provides an opportunity to claim compensation without having to pay out-of-pocket fees. The Rosen Law Firm operates on a contingency fee basis, ensuring no financial risk for participating investors. To join the lawsuit or to inquire about the details, interested parties can visit Rosen Legal's website or reach the firm through a direct call to Phillip Kim, Esq. at 866-767-3653.

Important Dates

Individuals seeking to assert their interest as lead plaintiffs must act quickly, as the deadline for filing is set for September 28, 2026. The lead plaintiff plays a crucial role in directing litigation and representing the interests of other investors.

Choosing Legal Representation

The Rosen Law Firm encourages investors to choose legal representatives skilled in handling securities class actions. Their strong track record boasts hundreds of millions recovered for investors in previous cases, making them a reliable choice in this complex landscape.

Conclusion

As the legal proceedings unfold, investors in Capricor Therapeutics remain informed of their rights and options. The upcoming months will likely see heightened activities surrounding the case, and stakeholders are urged to keep abreast of developments. Participation in the class action not only provides a path to potential recovery but also facilitates accountability in corporate governance practices within publicly traded companies.

For more information on this lawsuit and how to participate, please refer to the Rosen Law Firm's provided links or contact their offices directly.

Stay Informed

Investors are also encouraged to follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook for real-time updates and further information pertinent to this case.